CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML

PURPOSE: Ponatinib is the only approved tyrosine kinase inhibitor (TKI) suppressing BCR-ABL1(T315I)-mutated cells in chronic myeloid leukemia (CML). However, due to side effects and resistance, BCR-ABL1(T315I)-mutated CML remains a clinical challenge. Hydroxyurea (HU) has been used for cytoreduction...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EBioMedicine
Autors principals: Schneeweiss-Gleixner, Mathias, Byrgazov, Konstantin, Stefanzl, Gabriele, Berger, Daniela, Eisenwort, Gregor, Lucini, Chantal Blanche, Herndlhofer, Susanne, Preuner, Sandra, Obrova, Klara, Pusic, Petra, Witzeneder, Nadine, Greiner, Georg, Hoermann, Gregor, Sperr, Wolfgang R., Lion, Thomas, Deininger, Michael, Valent, Peter, Gleixner, Karoline V.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6921367/
https://ncbi.nlm.nih.gov/pubmed/31761618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.11.004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars